- Home
- ETON vs JRS Comparison
ETON vs JRS Comparison
Compare ETON & JRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- JRS
- Stock Information
- Founded
- ETON 2017
- JRS 2001
- Country
- ETON United States
- JRS United States
- Employees
- ETON N/A
- JRS N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- JRS Finance/Investors Services
- Sector
- ETON Health Care
- JRS Finance
- Exchange
- ETON Nasdaq
- JRS Nasdaq
- Market Cap
- ETON 329.8M
- JRS 267.5M
- IPO Year
- ETON 2018
- JRS N/A
- Fundamental
- Price
- ETON $14.41
- JRS $8.53
- Analyst Decision
- ETON Strong Buy
- JRS
- Analyst Count
- ETON 3
- JRS 0
- Target Price
- ETON $18.67
- JRS N/A
- AVG Volume (30 Days)
- ETON 243.0K
- JRS 86.6K
- Earning Date
- ETON 03-13-2025
- JRS 01-01-0001
- Dividend Yield
- ETON N/A
- JRS 8.87%
- EPS Growth
- ETON N/A
- JRS N/A
- EPS
- ETON N/A
- JRS N/A
- Revenue
- ETON $34,677,000.00
- JRS N/A
- Revenue This Year
- ETON $22.25
- JRS N/A
- Revenue Next Year
- ETON $81.48
- JRS N/A
- P/E Ratio
- ETON N/A
- JRS N/A
- Revenue Growth
- ETON 5.64
- JRS N/A
- 52 Week Low
- ETON $3.03
- JRS $5.95
- 52 Week High
- ETON $15.00
- JRS $8.00
- Technical
- Relative Strength Index (RSI)
- ETON 62.22
- JRS 46.97
- Support Level
- ETON $13.09
- JRS $8.14
- Resistance Level
- ETON $14.35
- JRS $8.70
- Average True Range (ATR)
- ETON 1.13
- JRS 0.19
- MACD
- ETON 0.08
- JRS 0.03
- Stochastic Oscillator
- ETON 82.60
- JRS 67.24
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests primarily in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies. At least 75% of the Fund's managed assets will be in securities rated investment grade.